The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened last month.

It holds a boxed warning for risks of embryo-fetal toxicity, as well as infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD) or ...